| February 5, 2011 |
| 6:45AM - 7:45AM |
Breakfast |
| 7:00AM |
Registration |
| 7:45AM |
Welcome and Introductions and CME Pre Test |
Steven Rosen |
 |
| Session 1:
CRITICAL QUESTIONS IN THE TREATMENT OF LYMPHOMAS AND HODGKIN’S DISEASE Chair: Thomas Witzig |
|
| 8:00AM |
Case Study:
Devising the optimal treatment strategies for newly diagnosed and relapsed/refractory diffuse large B-Cell lymphoma (DLBCL) |
Leo Gordon |
| 8:20AM |
Case Study:
Progress in the treatment of mantle cell lymphoma: applying the results of the most current clinical trials for both newly diagnosed patients and relapsed patients, a longitudinal review |
André Goy |
| 8:40AM |
Case Study:
Additional therapies for follicular lymphoma: managing the challenge of multiple first-line treatment options |
Thomas Witzig |
| 9:00AM |
Point-CounterPoint:
Follicular lymphoma patients who relapse following initial therapy should receive traditional alternative systemic treatment options rather than a stem cell transplant.
- Audience votes pre and post debate via ARS
- Expert faculty reviews the audience votes and provides their additional perspectives
|
Pro: John Leonard
Con: TBD Sonali Smith |
| 9:30AM |
Roundtable Panel Discussion: Each faculty provides his perspective on the options for the Point-Counterpoint |
Session #1 Faculty |
| 9:45AM |
Q & A and Additional Patient Cases Submitted by the Learners |
Learners and Faculty |
| 10:00AM |
BREAK |
|
| 10:20AM |
Case Study: New systemic options for the management of Hodgkin’s Disease |
Anas Younes |
| 10:40AM |
Case Study: Peripheral T-Cell Lymphoma: Therapeutic Advances |
Owen O’Connor |
| 11:00AM |
Case Study: State-of-the Art Therapies for Primary Cutaneous T-Cell Lymphoma: Building the new treatment algorithm? |
Steven Rosen |
| 11:20AM |
Case Study:
Personalizing therapies for patients with chronic lymphocytic leukemia (CLL): What are the optimal clinical applications of chemotherapies and targeted therapies in the first-line setting? |
Shuo-Ma |
| 11:40AM |
Case Study:
Relapsed or refractory CLL: what are the optimal systemic therapies for these patients? |
Tate Shanafelt |
| 12:00PM |
Q & A and Additional Patient Cases Submitted by the Learners |
Learners and Faculty |
| 12:30AM |
LUNCH WITH THE EXPERTS |
|
|
| Session 2:
CRITICAL QUESTIONS IN THE TREATMENT OF MULTIPLE MYELOMA - Session Chair: Vincent Rajkumar |
|
| 1:30PM |
Case Study:
The optimal treatment of the non-transplant candidates with multiple myeloma: what are the emerging options and optimal strategies? |
Vincent Rajkumar |
| 1:50PM |
Case Study:
What are the optimal treatment strategies for transplant-eligible candidates with multiple myeloma? |
Nikhil Munshi |
| 2:10PM |
Q & A and Additional Patient Cases Submitted by the Learners |
Learners and Faculty |
| 2:30PM |
BREAK |
|
|
| Session 3:
CRITICAL QUESTIONS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA, CHRONIC MYELOGENOUS LEUKEMIA AND MYELODYSLASTIC SYNDROMES - Session Chair: Michael Deininger |
|
| 2:50PM |
Case Study: Treatment of Acute Lymphoblastic Leukemia (ALL) |
Tibor Kbasovics |
| 3:10PM |
Case Study:
Treatment of Myelodysplastic Syndromes: Update 2011 |
TBD Virginia Klimek |
| 3:30PM |
Case Study: Management of a newly diagnosed patient with Acute Promyelocytic Leukemia (APL) |
Martin Tallman |
| 3:50PM |
Case Study: New algorithms for initial therapy and relapse therapies of chronic myelogenous leukemia (CML). What are the optimal therapeutic options? |
Moshe Talpaz |
| 4:10PM |
Case Study: Best clinical practices for treating acute myeloid leukemia (AML): How do we integrate prognostic factors into optimal treatment decision-making? |
Michael Deininger |
| 4:30PM |
Roundtable Panel Discussion: Each faculty provides his or her perspective on the cases |
Learners and Faculty |
| 4:45PM |
Final Q & A |
Learners and Faculty |
| 5:00PM |
Concluding Remarks and Post-Activity CME questions. |
Steven Rosen |
